Osteoporosis News

Treatment with the anti-sclerostin monoclonal antibody romosozumab resulted in fewer new fractures in postmenopausal women with high-risk osteoporosis compared with alendronate, according to a press release from Amgen.

Today, the ACP released an updated evidence-based clinical practice guideline strongly recommending that physicians treat women with osteoporosis with denosumab or bisphosphonates, such as alendronate, risedronate or zoledronic acid, to reduce fracture risk.

Among postmenopausal women, investigators found the risk of fracture decreased with the use of hormone therapy. Moreover, the findings were particularly true for women with the highest genetic risk for fracture and low bone mineral density.

The FDA today approved an abaloparatide injection for the treatment of postmenopausal women with osteoporosis at high risk for fracture, according to a press release from Radius Health.

There are no clearly established effects of osteoporosis medications on bone mineral density, fracture risk and safety in patients with chronic kidney disease, according to findings published in Annals of Internal Medicine.

The National Center for Health Statistics of the CDC recently published data that offered a FRAX-based estimation of the 10-year probability of middle-aged adults to sustain either a hip or a major osteoporotic fracture.

Denosumab in the treatment of patients with osteoporosis did not show any increase in common adverse events in a long-term trial, according to recently published data.

In premenopausal South Asian women, researchers identified higher levels of urinary N-telopeptide — a by-product for bone resorption — compared with Caucasian women, according to recently published data. They also found fluctuating levels of vitamin D may be related to bone resorption and detrimental to bone health.

SAN DIEGO — Compared with women, men had a greater risk for death after an osteoporosis-related fracture, according to a press release and presentation at the American Academy of Orthopedic Surgeons Annual Meeting.

Screening and treatment for osteoporosis in postmenopausal women after a hip fracture is alarmingly low, with fewer than one in five women aged 50 years and older utilizing recommended services within 6 months of fracture, according to a recent study.